News
Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA).
Explore Allogene's innovative CAR-T therapies targeting cancer & autoimmune diseases. ASCO updates on ALLO-316 could validate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback